Penetration Testing in Hyderabad · Pharma & SaaS

Hyderabad penetration testing is shaped by the same bimodal buyer reality that defines our Hyderabad VAPT and SOC work — Genome Valley pharma + Patancheru / Bachupally formulation belt on one side, HITEC City SaaS + US-healthcare GCC on the other. The difference between Hyderabad pentest and Hyderabad VAPT is scope philosophy. VAPT is checklist-driven and regulator-format. Pentest is objective-led and scenario-driven. The two playbooks live in the same firm with two different methodology stacks, and the senior consultant selects the right one at kickoff based on the buyer's question. Macksofy's Hyderabad regional hub at HITEC City makes both playbooks reachable within two hours of any pharma plant or HITEC City office.

Pharma pentest objectives are specific to regulated-data flows. The buyer question is not 'find vulnerabilities in our eTMF' — that is the VAPT question. The pentest question is 'if a motivated actor wanted to corrupt our clinical-trial data integrity ahead of the next FDA Pre-Approval Inspection, how would they do it and would we catch them?'. The objective shapes the engagement — initial access via spear-phish against the QA director's office or via a vendor-portal compromise on the LIMS or CDS vendor's portal, post-exploitation via the QC lab workstation network into the LIMS data-export path, and the controlled-stop at the data-integrity boundary (no actual tampering, evidence-via-screenshot-plus-hash).

Lab-instrument workstation pentest is a Hyderabad pentest specialty that complements our VAPT walk-through methodology. HPLC, GC, dissolution-tester and balance instrument workstations integrated into LIMS or CDS (Empower, LabSolutions, OpenLAB CDS, Chromeleon) — these are valid initial-access and lateral-movement footholds in a pharma pentest scenario. Shared local-admin credentials on the analytical workstation, USB-mass-storage policy gaps, audit-trail-disable paths on the chromatography software, time-synchronisation drift, and the analytical-data-server lateral-movement path into the LIMS network. Pentest walk-throughs are done with a QA witness and the evidence is documented in 21 CFR Part 11 §11.10(e) terms.

SaaS pentest objectives in Hyderabad mirror the Bengaluru pattern but with strong US-healthcare / US-BFSI parent control overlay. The scope often targets the multi-tenant authz, the IAM Pass Role chain, the GitHub Actions OIDC trust path, and the customer-data-egress paths that US enterprise customers care about. For US-healthcare GCC scopes on Gachibowli or Q City, the pentest objective frequently includes a controlled HIPAA Security Rule §164.308-312 path traversal — the parent's compliance function uses the engagement as the annual HIPAA penetration-test attestation.

Identity is the third Hyderabad pentest pillar. Pharma clients run hybrid identity (on-premises AD federated to Azure AD or Okta) with multiple regional-language Bhashini frontends, lab-network-isolated identity domains, and CRO-sponsor-side federated identity for clinical-trial-portal access. SaaS clients run more conventional Okta or Microsoft Entra ID-federated topologies. Both have non-trivial privilege-escalation paths — ADCS misconfigurations on the on-premises forest, AD Connect privilege spikes on the AAD-side, and the SCIM-provisioning impersonation paths that enterprise-customer-driven SaaS exposes.

Procurement reality matters. Pharma pentest engagements close through the IT head and the QA director with the head of QC or plant operations copied if lab-instrument scope is included. The scope is signed only after the QA team confirms validation-state preservation and the inspection-defence rehearsal pack covers the post-engagement evidence trail. SaaS / GCC pentest closes through the CTO and AppSec lead, sometimes with the US parent's regional CISO copied for the larger GCCs. Engagement letters include trespass-and-deception waivers, QA-witness scheduling and (for GMP-validated lab-instrument scope) explicit no-state-alteration acknowledgement.

DPDP §16 cross-border-transfer evidence is layered into every Hyderabad pentest. Pharma sponsor-data flows back to US or EU CRO parents, SaaS customer data flows to global customer base, US-healthcare GCC PHI flows back to US-parent. Each requires DPDP §16 cross-border-transfer-control evidence. The pentest documents the cross-border-data-flow paths exercised in the engagement and the contractual-safeguard reference per flow.

Onsite cadence is dictated by Hyderabad geography. HITEC City regional hub means two-hour onsite SLA across Madhapur, Gachibowli, Banjara Hills, Kondapur and the Genome Valley pharma belt. Patancheru / Bachupally / Shameerpet sites are 60-90 minutes from the hub. Pharma pentest engagements typically run 5-6 weeks with two onsite legs (kickoff at the QA director's office, closing readout at the IT director's office). SaaS pentest engagements run 3-4 weeks with one HITEC City kickoff onsite. For US-healthcare GCC engagements with US-parent reporting needs, the closing readout includes a virtual call with the US parent's regional CISO.